Irritable bowel syndrome in the light of Rome consensus III (2006): 10 years later


Cite item

Full Text

Abstract

Irritable bowel syndrome (IBS) is the most common diagnosis in gastroenterology. Over 10 years after Rome consensus III (2006), there has been much new information on the pathogenesis of IBS and its therapy options. The paper analyzes basic investigations that have contributed to the theory of this disease and to a better quality of life in patients.

References

  1. Маев И.В., Кучерявый Ю.А., Черемушкин С.В. Эволюция представлений о синдроме раздраженного кишечника. М.; 2013.
  2. Liu J, Wei X, Zhao C, Hu S, Duan J, Ju G, Wong-Riley MT, Liu Y. 5-HT induces enhanced phrenic nerve activity via 5-HT2A receptor/PKC mechanism in anesthetized rats. Eur J Pharmacol. 2011;657:67-75. doi: 10.1016/j.ejphar.2011.01.048.
  3. Hua MC, Chao HC, Yao TC, Lai MW, Huang JL. Investigation of interleukin-10 promoter polymorphisms and interleukin-10 levels in children with irritable bowel syndrome. Gut Liver. 2013;7:430-436. doi: 10.5009/gnl.2013.7.4.430.
  4. Saito YA, Larson JJ, Atkinson EJ, Ryu E, Almazar AE, Petersen GM, Talley NJ. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 2012;57:2650-2657. doi: 10.1111/apt.13094.
  5. Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol. 2009;9:6-9. doi: 10.1186/1471-230x-9-6.
  6. Coutinho SV, Plotsky PM, Sablad M, Li Y, Nie Y, Xie J et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci. 2000;52:2942-2949.
  7. Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology. 2006;130(5):1377-1390. doi: 10.5056/jnm15016.
  8. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136(6):1979-1988. doi: 10.1111/nmo.12529.
  9. Парфенов А.И., Ручкина И.Н., Атауллаханов Р.И., Белая О.Ф., Чикунова Б.З., Пичугин А.Ф., Кожемякина Е.Ш. Постинфекционный синдром раздраженного кишечника. Терапевтический архив. 2009;81(2):39-45.
  10. Парфенов А.И., Ручкина И.Н. Постинфекционный синдром раздраженного кишечника. Лечащий врач. 2010;7:16-19.
  11. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastoenterol. 2014;20(10):2470-2481. doi: 10.4166/kjg.2015.66.4.202.
  12. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol. 2014;20(10):2456-2469. doi: 10.1097/md.0000000000001934.
  13. Парфенов А.И. Энтерология. Изд. 2-е. М.: Медицинское информационное агентство; 2009.
  14. Gracie DJ, Ford AC. IBS-like symptoms in patients with ulcerative colitis. Clin Exper Gastroenterol. 2015;8:101-109. doi: 10.1053/j.gastro.2015.09.024.
  15. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19(8):861-870. doi: 10.1111/j.1365-2036.2004.01929.x.
  16. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-754. doi: 10.1053/j.gastro.2009.01.015.
  17. Chey WD, Kurlander J, Eswaran S. Irritable Bowel Syndrome. A Clinical Review JAMA. 2015;313(9):949-958. doi: 10.1001/jama.2015.0954.
  18. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6(7):765-771. doi: 10.1016/j.cgh.2008.02.058.
  19. Carroccio A, Mansueto P, D’Alcamo A, Iacono G. Non-celiac wheat sensitivity as an allergic condition: personal experience and narrative review. Am J Gastroenterol. 2013;108(12):1845-1852. doi: 10.1038/ajg.2013.353.
  20. Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, Kaukinen K, Rostami K, Sanders DS, Schumann M, Ullrich R, Villalta D, Volta U, Catassi C, Fasano A. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10:13-24. doi: 10.1186/1741-7015-10-13.
  21. Biesiekierski JR, Newnham ED, Shepherd SJ, Muir JG, Gibson PR. Characterization of adults with a self-diagnosis of nonceliac gluten sensitivity. Nutr Clin Pract. 2014;29(4):504-509. doi: 10.1177/0884533614529163.
  22. Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O’Neill J, Carlson P, Lamsam J, Janzow D, Eckert D, Burton D, Zinsmeister AR. A controlled trial of gluten-free diet in patients with irritable bowel syndrome diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903-911. doi: 10.1053/j.gastro.2013.01.049.
  23. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75. doi: 10.1053/j.gastro.2013.09.046.
  24. Palomba S, Di Cello A, Riccio E, Manguso F, La Sala GB. Ovarian function and gastrointestinal motor activity. Minerva Endocrinol. 2011;36:295-310.
  25. Guarino M, Cheng L, Cicala M, Ripetti V, Biancani P, Behar J. Progesterone receptors and serotonin levels in colon epithelial cells from females with slow transit constipation. Neurogastroenterol Motil. 2011;23(6):575-e210. doi: 10.1111/j.1365-2982.2011.01705.x.
  26. Labus JS, Dinov ID, Jiang Z, Ashe-McNalley C, Zamanyan A, Shi Y, Hong JY, Gupta A, Tillisch K, Ebrat B, Hobel S, Gutman BA, Joshi S, Thompson PM, Toga AW, Mayer EA. Irritable bowel syndrome in female patients is associated with alterations in structural brain networks. Pain. 2014;155(1):137-149. doi: 10.1016/j.pain.2013.09.020.
  27. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40(1):66-73. doi: 10.1007/s12016-010-8203-5.
  28. Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(27):8867-8885. doi: 10.3748/wjg.v20.i27.8867.
  29. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, Bartesaghi G, Canovi B, Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proofof-concept study. Aliment Pharmacol Ther. 2009;30(3):245-252. doi: 10.1111/j.1365-2036.2009.04041.x.
  30. Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(3):374-383. doi: 10.1111/j.1365-2036.2011.04732.x.
  31. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3): 329-341. doi: 10.1111/j.1365-2036.2008.03881.x.
  32. Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O’Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010; 139(6):1877-1886. doi: 10.1053/j.gastro.2010.08.041.
  33. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714-1724. doi: 10.1038/ajg.2012.255.
  34. Эпштейн О.И. Сверхмалые дозы (история одного исследования). М.: Издательство РАМН; 2008.
  35. Эртузун И.А., Зуева Е.П., Крылова С.Г., Ефимова Л.А., Дугина Ю.Л., Эпштейн О.И. Экспериментальное изучение «Колофорта» — нового препарата для лечения синдрома раздраженного кишечника и других функциональных заболеваний желудочно-кишечного тракта. Вестник ВолгГМУ. 2012;4:25-27.
  36. Авалуева Е.Б., Адашева Т.В., Бабаева А.Р., Бурдина Е.Г., Киреева Н.В., Ленская Л.Г., Осадчук М.А., Пахомова И.Г., Попова Л.И., Ткаченко Е.И., Успенский Ю.П., Шварц Ю.Г., Мысливец А.А., Андрианова Е.Н. Эффективность и безопасность применения Колофорта при синдроме раздраженного кишечника: итоги многоцентрового двойного слепого плацебо-контролируемого рандомизированного клинического исследования. Гастроэнтерология. 2014;1:43-50.
  37. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Фармакотерапия синдрома раздраженного кишечника с позиций доказательной медицины. Терапевтический архив. 2015;2:5-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies